Compound ID | 442
Synonym(s): MC 02479 | RWJ 54428 | MC-02479
Class: Beta-lactam
| Agent Type: | Semisynthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Combined with other compounds: | Could be combined with aztreonam, fosfomycin, gentamicin or levofloxacin for empiric therapy |
| Description: | Chamberland S, Blais J, Hoang M, et al. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria. Antimicrob Agents Chemother. 2001;45(5):1422-30. |
| Institute where first reported: | Johnson & Johnson Pharmaceutical R&D, USA; Essential Therapeutics [Ceased] |
| Year first mentioned: | 1997 |
| Highest development stage: | Phase 1 |
| Development status: | Inactive |
| Reason dropped: | This was to be developed as an anti-MRSA Cephalosporin [as its prodrug]. May have been dropped in favour of ceftobiprole which J&J were also developing at the same time |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/9873517 |
| Guide to Pharmacology: | MC-02479 |
| Citations: |
|